Investor FAQs

Where is Akero Therapeutics’ corporate headquarters?


Akero Therapeutics

601 Gateway Boulevard, Suite 350
South San Francisco, CA 94080
On what stock exchange are Akero Therapeutics’ shares traded, and what is the ticker symbol?
Our common stock is traded on the NASDAQ Global Select Market under the ticker symbol, AKRO.
When did Akero Therapeutics go public?
Our initial public offering took place on June 19, 2019.
Does Akero Therapeutics pay dividends?
We do not expect to pay any cash or other dividends on our common stock neither now nor in the foreseeable future.
Who is Akero Therapeutics’ transfer agent?
Communication regarding transfer requirements, lost certificates and changes of address should be directed to:

Computershare Trust Company, N.A.
Who is Akero Therapeutics’ legal counsel and auditors?
Our legal counsel is:
Goodwin Procter LLP

Our independent auditor is:
Deloitte & Touche LLP
How can I view documents Akero Therapeutics has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?
Our quarterly and annual reports, as well as other SEC filings, can be found on the Financials & Filings portion of the Investor Relations website or directly from the SEC at www.sec.gov